Beam Therapeutics (BEAM): The Next Frontier in Biotech
State Street Corp's Strategic Acquisition in Beam Therapeutics Inc
Beam Therapeutics Insider Sold Shares Worth $1,342,752, According to a Recent SEC Filing
Scotiabank Initiates Beam Therapeutics at Sector Perform With $24 Price Target
Form 144 | Beam Therapeutics(BEAM.US) Officer Proposes to Sell 4.27 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Oct 7, $Beam Therapeutics(BEAM.US)$ Officer Burrell Terry-Ann intends to sell 185.57K shares of its common stock on Oct 7, with a total market value of approximately $4.27
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation